B-cell receptor specific for Human Papillomavirus type 16 and 18 L1 virus-like particles (HPV-16/18 L1-specific BCR)

B-cell receptors (BCRs) specific for conformational epitopes on HPV-16 and HPV-18 L1 virus-like particles (VLPs) are the primary immunological targets for prophylactic HPV vaccines. These receptors are membrane-bound immunoglobulins found on the surface of naïve B cells that possess the unique specificity to recognize the complex three-dimensional structure of the L1 capsid protein [PMID: 12633335]. Upon binding to the VLP antigens, these BCRs initiate intracellular signaling pathways that drive the expansion of antigen-specific B-cell clones. This process is critical for the generation of high-affinity neutralizing antibodies and long-lived memory B cells, which provide protection against subsequent infection by high-risk HPV types 16 and 18 [WHO]. Because HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancer cases globally, the activation of these specific BCRs is a cornerstone of cancer prevention strategies [NCI]. The interaction is highly dependent on the 'conformational' nature of the epitopes, meaning the BCRs recognize the specific quaternary structure of the assembled VLP rather than just the linear amino acid sequence of the L1 protein. Successful engagement of these receptors by vaccines leads to robust, long-lasting humoral immunity that effectively prevents the virus from establishing an infection in the host epithelium.

Other names

Naïve B-cell receptor for HPV L1 VLPAnti-HPV L1 B-cell receptorHPV-specific BCRHuman Papillomavirus L1-specific immunoglobulin receptor

The vaccine antigens, which are recombinant L1 virus-like particles (VLPs), act as ligands that bind to specific B-cell receptors (BCRs) on the surface of naïve B cells. This binding event, which is highly dependent on the recognition of conformational epitopes, triggers BCR clustering and downstream signaling pathways (such as the MAPK and PI3K pathways). This signaling induces the B cells to undergo activation, proliferation, and differentiation into high-affinity antibody-secreting plasma cells and long-lived memory B cells, providing prophylactic immunity against HPV infection [PMID: 25403868, CDC].